Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1630351 | 0.90 | GBA1 (0.42) | CSNK2A2CSNK2A1GBA1CCNT1MAPT | |
| SCHEMBL1630790 | 0.88 | GBA1 (0.35) | CSNK2A2CSNK2A1GBA1LMNAMAPT | |
| SCHEMBL1630876 | 0.88 | KDM4E (0.33) | CSNK2A2CSNK2A1GBA1RPS6KB1AKT1 | |
| SCHEMBL1630804 | 0.87 | CCNC (0.34) | CSNK2A2CSNK2A1GBA1LMNAMAPT | |
| SCHEMBL1632239 | 0.87 | MAPT (0.33) | CSNK2A2CSNK2A1GBA1RPS6KB1AKT1 | |
| SCHEMBL1631033 | 0.86 | ADORA2A (0.35) | GBA1LMNAMAPTADORA2AGPR84 | |
| SCHEMBL1631283 | 0.86 | GBA1 (0.37) | CSNK2A2CSNK2A1GBA1RPS6KB1AKT1 | |
| SCHEMBL1630640 | 0.85 | CSNK2A2 (0.33) | CSNK2A2CSNK2A1GBA1RPS6KB1AKT1 | |
| SCHEMBL1631819 | 0.85 | NPC1 (0.36) | CSNK2A2CSNK2A1GBA1CCNT1LMNA | |
| SCHEMBL1630361 | 0.85 | GBA1 (0.41) | CSNK2A2CSNK2A1GBA1CCNT1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-01-08 | — | — | US | claimed |
| US-7932270-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | CSNK2A2 595/4885CSNK2A1 835/4885GBA1 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.